Nanomedicines, LNPs & Viral Vectors
We aims to play a pivotal role in advancing LNP, nanomedicine, and gene therapy vector development
Vesiculab aims to facilitate LNP, nanomedicine, and gene therapy vector development, by offering products that enhance the capability of analytical platforms, as well as improving sample preparation. Leveraging techniques such as flow cytometry, nanoparticle tracking analysis (F-NTA), fluorescence microfluidic resistive pulse sensing (FMRPS), and confocal microscopy in combination with Vesiculab products enables researchers to delve into the intricate world of advanced nanoparticles with unprecedented precision.
Specifically, it has developed solutions for sample labelling (Vesi-Dye LMB-600) and cleaning (Vesi-SEC micro ) that offer a pathway to faster and more efficiency analytics, such as empty/full cargo analysis, as well as cell-uptake assays in LNPs, liposomes and lentiviruses.
By providing state-of-the-art tools and expertise, Vesiculab aims to play a pivotal role in advancing these fields, ultimately driving innovation and accelerating the development of transformative therapies for a myriad of medical conditions.
Discover our advanced solutions for research in the field of extracellular vesicles (EVs), nanomedicines, gene therapy and nanoparticle-based vaccines.
Extracellular Vesicles
By providing reliable solutions, Vesiculab significantly elevates the efficiency and reliability of extracellular vesicle research, accelerating progress in this dynamic field of scientific research.
